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The ARF/MDM2/p53 pathway is a principal defense mechanism to protect the organism from uncontrolled
effects of deregulated oncogenes. Oncogenes activate ARF, which interacts with and inhibits the ubiquitin
ligase MDM2, resulting in p53 stabilization and activation. Once stabilized and activated, p53 can either
induce or repress a wide array of different gene targets, which in turn can regulate cell cycle, DNA repair, and
a number of apoptosis-related genes. Here we show that, unlike p53, p63, a member of the p53 family, directly
interacts with p14ARF. Through this interaction ARF inhibits p63-mediated transactivation and transrepres-
sion. In p63-transfected cells, ARF, which normally localizes into nucleoli, accumulates in the nucleoplasm.
Based on these observations, we suggest that stimuli inducing p14ARF expression can, at the same time, activate
p53 and impair p63 transcriptional activity, altering the pattern of p53 target gene expression. Here we show,
for the first time, a physical and functional link between the p14ARF tumor suppressor protein and p63, a
member of the p53 family.
The ARF tumor suppressor protein (known as p14ARF in
humans and p19ARF in mice) is a product of the alternative
reading frame of the human INK4a locus on chromosome
9p21. The ARF tumor suppressor induces potent growth arrest
or cell death in response to hyperproliferative oncogenic stim-
uli. ARF can activate the p53 tumor surveillance pathway by
interacting with and inhibiting the p53-antagonist, MDM2
(29). ARF limits the E3 ubiquitin ligase activity of MDM2 (14),
thus preventing the polyubiquitination, nuclear export, and
subsequent cytoplasmic degradation of p53 (47). Once stabi-
lized and activated, p53 can either activate or repress a wide
array of different gene targets, which in turn can regulate cell
cycle, DNA repair, and a number of apoptosis-related genes
(28).
In addition to p53, mammalian cells contain two homolo-
gous genes, p63 and p73. These genes give rise to the expres-
sion of proteins that are highly similar to p53 in structure and
function. In particular, p63 and p73 proteins can induce p53-
responsive genes and elicit programmed cell death (16, 17, 25,
46).
Unlike p53, both p63 and p73 exist in multiple isoforms. In
the case of p63, at least six different isotypes with widely dif-
fering transactivation potentials have been described (46). The
transactivating (TA) isoforms, which resemble p53, are gener-
ated by the use of an upstream promoter; the N isoforms,
produced from an intronic promoter, contain the same DNA-
binding and oligomerization (OD) domains as the TA isoforms
but lack the transactivation domain. The N isoforms contain
a region of 26 amino acids at the very N-terminal end of the
protein (TA2) in which a further activation function was re-
cently mapped (8). Both the TA and N isoforms have three
possible carboxyl termini, termed , , and . In the C-terminal
extension of the  isoforms there is a sterile alpha motif (SAM)
that is found in proteins that regulate mammalian develop-
ment and is thought to be involved in protein-protein interac-
tions (36).
Despite the structural similarities, a number of functional
differences were found between p53, p63, and p73 proteins that
could depend on the biochemical properties of the proteins but
could also derive from differences in the expression pattern.
p73 and p63 are more important during development and
differentiation. In particular, p63 appears to be primarily im-
plicated in epithelial and limbs development (37). However, it
is interesting that UVB-induced DNA damage decreases levels
of the dominant-negative N-p63 isoform; simultaneously,
the levels of the TA-p63 isoforms increase (20). Downregula-
tion of Np63, as well as TAp63 upregulation, may be a
prerequisite for UV-induced apoptosis in skin. This notion is
supported by the recent observation that the TAp63 isoform
is required for p53-dependent apoptosis induced by DNA
damage, implying a role for p63 in preventing stress-induced
DNA damage and tumorigenesis (8, 10). Furthermore, it has
recently been reported that a balance between TA and N p63
isoforms is required to allow cells to respond to signals re-
quired for maturation of embryonic epidermis (18), suggesting
the existence of a complex mechanism by which relative
amount of the individual p63 isoforms can be regulated.
The p53 protein is a labile protein whose levels are primarily
controlled by the MDM2/ARF pathway (12, 19). However,
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although regulation of p53 by the p14ARF-MDM2 circuitry is
well understood, very little is known about whether and how
this molecular pathway regulates the functions of the p53 ho-
mologues. Remarkably, p73 can also associate with MDM2 (2),
as would be expected from its strong homology with p53 and its
activity is modulated by MDM2. Moreover, we have demon-
strated that MDM2 induces TAp63 protein stabilization and
transcriptional activation (3). Here we show, for the first time,
a physical and functional association between p14ARF and p63.
Our study suggests a mechanism by which p14ARF might dif-
ferentially regulate the expression of p53-target genes through
the complex network of p53-like proteins.
MATERIALS AND METHODS
Plasmids. All of the p63 cDNAs in the pcDNA3 vector were kindly provided
by H. van Bokhoven (38). A pcDNA3.1/HisTAp63 plasmid was used in elec-
trophoretic mobility shift assays (EMSAs). To obtain the construct TAp63(297-
499), pcDNA3-TAp63 was cut with EcoRI and religated in order to eliminate
the last C-terminal 609 bp of TAp63, whereas Np63(1-26) and Np63(1-
86) were obtained by PCR with either 1-26F or 1-86F primers and the reverse
primer and pcDNA3-Np63 as a template (1-26F, CCGCTCGAGGACCAG
CAGATTCAG; 1-86F, CCGCTCGAGTTCCAGCAGTCAAGC; reverse
primer, GTGAATTCAGTGCCAACCTGTGGT).
The mutant plasmid pcDNA-p14ARF(1-38) was obtained as follows: a NarI-
XbaI fragment was excised from pcDNA3-ARF and, after filling of the NarI site,
it was cloned in EcoRV-XbaI sites of pcDNA3. The plasmid pcDNA-
p14ARF(66-132) was obtained as follows. A HindIII-XbaI fragment was excised
from N-p19 plasmid (4) and, after filling of the HindIII site, it was cloned in
EcoRV-XbaI sites of pcDNA3.
The HindIII 1.08-kb fragment containing the apoptosis protease-activating
factor 1 (Apaf1) promoter sequence was retrieved from the pGL3b-Apaf-
prom(871/208) plasmid provided by K. Helin (23) and ligated in the HindIII
site of the pCAT0 plasmid to give the Apaf1CAT plasmid.
The other plasmids have been already described (3, 11).
Cell culture and transfection. H1299, Saos-2, COS-7, and HaCaT cells were
cultured in Dulbecco modified Eagle medium supplemented with 10% fetal
bovine serum. NIH 3T3 cells were cultured in Dulbecco modified Eagle medium
supplemented with 10% calf serum. H1299 and NIH 3T3 cells were transfected
by using Lipofectamine and Lipofectamine supplemented with Plus (Gibco),
respectively. Saos-2 and COS-7 cells were transfected with Lipofectamine 2000
(Gibco). HaCaT cells were transfected with Superfect reagent (Qiagen) accord-
ing to the manufacturer’s instructions. The total amount of transfected DNA was
kept constant by using the “empty” expression vector when necessary.
Western blotting. At 48 h after transfection cells were lysed in 10 mM Tris-HCl
(pH 7.5), 1 mM EDTA, 150 mM NaCl, 1 mM dithiothreitol, 1 mM phenylmeth-
FIG. 1. p63 transactivates the Apaf1 promoter. (A) H1299 cells were transiently cotransfected with 0.5 g of the Apaf1CAT reporter
plasmid/dish and the indicated amounts of each p63-expressing plasmid. After 48 h, cells were harvested, and the CAT activity was determined.
The basal activity of the reporter was set to 1. The data are presented as the fold induction relative to the sample without effector. Each histogram
bar represents the mean of three independent transfection duplicates. The standard deviations are indicated. (B) Expression of transfected
proteins. H1299 cells were transiently transfected with 0.5 g of the indicated plasmids. At 48 h after transfection cells were lysed and 50 g of
the lysates were immunoblotted with anti-myc antibodies.
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ylsulfonyl fluoride, 0.5% sodium deoxycholate, and protease inhibitors. Cell
lysates were incubated on ice for 30 min, and the extracts were centrifuged at
13,000 rpm for 10 min to remove cell debris. Protein concentrations were deter-
mined by the Bio-Rad protein assay. After the addition of 4 loading buffer (2%
sodium dodecyl sulfate [SDS], 30% glycerol, 300 mM -mercaptoethanol, 100
mM Tris-HCl [pH 6.8]), the samples were incubated at 95°C for 5 min and
resolved by SDS-polyacrylamide gel electrophoresis. Proteins were transferred to
a polyvinylidene difluoride membrane (Millipore) and probed with the following
antibodies: anti-p63 (H137 or 4A4; Santa Cruz), anti-p14ARF (C-18; Santa Cruz),
anti-MDM2 (smp14; Santa Cruz), anti-p21 (C-19; Santa Cruz), anti-myc (sc40;
Santa Cruz), and anti-actin (I-19; Santa Cruz). Proteins were visualized by an
enhanced chemiluminescence method (Amersham).
Coimmunoprecipitations. NIH 3T3, H1299, or HaCaT cells (5  105/60-mm
plate) were transfected with the indicated vectors. Transfected cells were har-
vested 48 h posttransfection, and the cell lysates were prepared as described
above. Lysates containing 500 g of proteins were precleared with 30 l of
protein A-agarose (50% slurry; Santa Cruz) and then incubated overnight at 4°C
with fresh protein A-beads (30 l) and 2 g of anti-p63 (H137 or 4A4; Santa
Cruz) or anti-p14ARF (C-18; Santa Cruz) antibodies. The beads were washed
vigorously twice with lysis buffer and once with radioimmunoprecipitation assay
buffer and loaded directly onto an SDS–12% polyacrylamide gel. The immuno-
precipitated proteins were detected by Western blotting. For the coimmunopre-
cipitations of in vitro-translated proteins, TAp63, p14ARF, p14ARF(1-38) and
p14ARF(66-132) proteins were in vitro translated in the presence of [35S]me-
thionine by using TnT reticulocytes from Promega with 1 g of pcDNA3-
TAp63 and 1 g of pcDNA3 or with 1 g of pcDNA3-TAp63 and 1 g of
either pcDNA3-p14ARF, pcDNA3-p14ARF(1-38), or pcDNA3-p14ARF(66-
132). Then, 40-l portions of the individual reactions were used for immuno-
precipitation with anti-His antibodies (6xHis; Clontech).
EMSA. EMSA experiments were performed as already described (26).
TAp63 and p14ARF proteins were in vitro translated by using TnT reticulocytes
from Promega with 0.5 g of pcDNA3.1/His-TAp63, 1.5 g of pEGFP C3, 1.5
g of pcDNA3-p14ARF, 0.5 g of pEGFP C3, 0.5 g of pcDNA3.1/His-TAp63,
and/or 1.5 g of pcDNA3-p14ARF. Next, 10 l of the individual reactions was
used either for the binding reaction or for Western blot analysis. The probe is a
radiolabeled oligonucleotide duplex containing a p53-binding site present in the
p21 promoter (p21.1 described in reference 44). A 100-fold molar excess of the
same cold oligonucleotide or an oligonucleotide containing a consensus binding
site for E2F1 was used for competition experiments. For the supershift antibod-
ies against the His tag fused at the 5	 of pcDNA3.1/His-TAp63 (6xHis), anti-p63
antibodies (H-137; Santa Cruz) or unrelated polyclonal anti-p21 antibodies (C-
19; Santa Cruz) were used, adding them to the samples prior to the binding
reaction (30 min in ice).
Subcellular distribution assay. NIH 3T3, COS-7, Saos-2, and H1299 cells
(105/35-mm plate) were grown on micro cover glasses (BDH) and transfected
with the indicated vectors. At 24 h after transfection, cells were washed with cold
phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde (Sigma-
Aldrich) for 15 min at 4°C. After being washed with PBS, the cells were perme-
abilized with ice-cold 0.5% Triton X-100 (COS-7 and NIH 3T3 cells) or 0.1%
Triton X-100 (Saos-2 and H1299 cells) for 10 min and then washed with PBS,
incubated with DAPI (4	,6	-diamidino-2-phenylindole; 10 mg/ml [Sigma-Al-
drich]) for 3 min, and washed again with PBS. Finally, the glasses were mounted
with Mowiol (Sigma-Aldrich). The cells were examined under a fluorescence
microscope (Nikon). All images were digitally processed by using Adobe Pho-
toshop software. To analyze ARF localization, before incubation with DAPI,
cells were blocked with 5% fetal bovine serum in PBS for 30 min, washed with
PBS, and then incubated with anti-His polyclonal antibodies (Invitrogen) at 37°C
for 1 h. After being washed with PBS three times, cells were incubated with a
secondary antibody (Cy3-conjugated anti-mouse immunoglobulin G; Immu-
noResearch Laboratory) at room temperature for 30 min.
CAT assay. H1299 and Saos-2 cells (5  105 cells/60-mm dish) were transiently
cotransfected, as described above, with Apaf1CAT (0.5 g), WAF1CAT (0.4
g), or Hsp70CAT (0.25 g) promoter reporter constructs and the indicated
amounts of the expression plasmids encoding each p63 isoform or p53 with or
without the indicated amount of pcDNA-p14ARF. Cells were collected 48 h after
transfection. Equal amounts of cell extracts (10 to 30 g), determined by the
Bradford method (Bio-Rad), were assayed for chloramphenicol acetyltransferase
(CAT) activity by using 0.1 Ci of [14C]chloramphenicol and 4 mM acetyl
coenzyme A. Separated products were detected and quantified by using a Phos-
phorImager (Molecular Dynamics) and ImageQuant software. The pCMV-gal
plasmid (1.5 g) was used to normalize CAT values for transfection efficiency.
RESULTS
p14ARF inhibits p63 transcriptional activity. Under condi-
tions of genotoxic stress or hyperproliferative stimuli, p53 sta-
bilization leads to transcriptional activation and repression of
different sets of genes involved in the control of cell prolifer-
ation and genomic-repair processes (5, 34). Some of them,
such as p21, MDM2, BAX, GADD45, and 14-3-3
 (37) are
also activated by p63. Depending on the specific p63 isoform
and promoter sequence being tested, wild-type p63 can be
either a transcriptional activator, a repressor, or a dominant-
negative repressor of the transactivation function (11).
Among the known p53 target promoters, we found that the
Apaf1 promoter is efficiently upregulated by all p63 isoforms,
with the exception of Np63 (Fig. 1A). The apoptosis pro-
tease-activating factor 1 (Apaf1) is a proapoptotic gene that
has been demonstrated to be involved in several cell death
pathways (13). Figure 1A shows the transcriptional activities
and dose responses of the different p63 isoforms on the Apaf1
promoter. In this experiment, we used H1299 cells, a p53-null
human lung carcinoma-derived cell line expressing undetect-
able levels of p63 and p73 (data not shown). Expression of p63
FIG. 2. p63 transactivation is inhibited upon p14ARF transfection.
H1299 cells were transiently cotransfected with the indicated combi-
nations of the following expression plasmids (total DNA 2 g):
Apaf1CAT reporter plasmid (500 ng/dish; bars 1 to 12), a fixed amount
of p14ARF (200 ng/dish; gray hatched bars) or pcDNA (200 ng/dish,
open bars) and increasing amounts (25 ng, bars 3 to 4; 50 ng, bars 5 to
6; 75 ng, bars 7 to 8; 100 ng, bars 9 to 10; 200 ng, bars 11 to 12) of TA
(A)- or N p63 (B)-expressing plasmids. After 48 h, cells were har-
vested, and the CAT activity was determined. The basal activity of the
reporter was set to 1. The data are presented as the fold induction
relative to the sample without effector. Each histogram bar represents
the mean of three independent transfection duplicates. The standard
deviations are indicated.
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proteins, upon transfection into H1299, was verified by West-
ern blotting and immunodetection with anti-myc antibodies
that recognize the myc epitope at the N-terminal of all trans-
fected proteins. Figure 1B shows that the relative abundance of
transfected proteins, expressed from pcDNA3 vectors, varies
to some extent, with TA being the more abundant and TA
and TA being the less abundant, in agreement with published
results (11).
To investigate the effects of ARF on p63-dependent tran-
scription, we transiently cotransfected H1299 cells with the
Apaf1CAT reporter construct, increasing the amounts of ei-
ther TAp63, Np63, TAp63, TAp63, or Np63 expres-
sion vectors and a fixed amount of p14ARF. Our results clearly
indicate that ARF is able to inhibit both TA and N-mediated
transactivation (Fig. 2 and data not shown). In Fig. 2 are
shown, as representative examples, results obtained with TA
and Np63. Similar experiments were performed with a dif-
ferent target promoter, p21WAF, and the TAp63 and  iso-
forms as transactivators, and similar results were obtained
(data not shown).
Next, we decided to confirm the observed inhibitory effect of
p14ARF on p63-driven transcription on a different cellular con-
text. We used Saos-2 cells, a human osteosarcoma-derived cell
line, expressing neither p53 nor p63. We transiently cotrans-
fected into Saos-2 cells the Apaf1 or p21WAF CAT reporters
and a fixed amount of TAp63 (0.1 g) alone or with increas-
ing amounts of p14ARF-expressing plasmid (0.2, 0.4, and 0.8
g). As shown in Fig. 3A, increasing expression of ARF re-
FIG. 3. p14ARF inhibits TA- and Np63-dependent transactivation. (A) Saos-2 cells were transiently cotransfected with the Waf1CAT (0.4
g/dish, open bars) or the Apaf1CAT (0.5 g/dish, gray bars) reporter plasmids, a fixed amount of TAp63 (0.1 g/dish, bars 5 to 12) or increasing
amounts of p14ARF (0.2 g/dish, bars 7 and 8; 0.4 g/dish, bars 9 and 10; 0.8 g/dish, bars 3, 4, 11, and 12) expressing plasmids. After 48 h, cells
were harvested, and the CAT activity was determined. (B) Saos-2 cells were transiently cotransfected with 0.5 g of Apaf1CAT reporter plasmid
(bars 1 to 6), a fixed amount of Np63 (0.1 g/dish, bars 3 to 6) and increasing amounts of p14ARF (0.2 g/dish, bar 4; 0.4 g/dish, bar 5; 0.8
g/dish, bars 2 and 6)-expressing plasmid. After 48 h, cells were harvested, and the CAT activity was determined. The basal activity of the reporter
was set to 1. The data are presented as the fold induction relative to the sample without effector. Each histogram bar represents the mean of three
independent transfection duplicates. The standard deviations are indicated. (C) Saos-2 cells were transiently cotransfected with the Waf1CAT (0.4
g/dish, open bars) or the Apaf1CAT (0.5 g/dish, gray bars) reporter plasmid, a fixed amount of p53 (0.1 g/dish, bars 5 to 12), and increasing
amounts of p14ARF (0.2 g/dish, bars 7 and 8; 0.4 g/dish, bars 9 and 10; 0.8 g/dish, bars 3, 4, 11, to 12)-expressing plasmids. After 48 h, cells
were harvested, and the CAT activity was determined. The basal activity of the reporter was set to 1. The data are presented as the fold induction
relative to the sample without effector. Each histogram bar represents the mean of three independent transfection duplicates. The standard
deviations are indicated. (D) Saos-2 cells were transiently cotransfected with 0,5 g of p63 (lanes 2 to 5) and increasing amount of
p14ARF-expressing plasmid (1.0 g/dish, lane 4; 2.0 g/dish, lane 5; 4.0 g/dish, lanes 1 and 5). At 48 h after transfection the cells were lysed, and
25 g of the lysates was immunoblotted with anti-p63 and anti-p14ARF antibodies. (E) Saos-2 cells were transiently cotransfected with 0.5 g of
Np63 (bars 2 to 5) and increasing amounts of p14ARF-expressing plasmids (1.0 g/dish, bar 3; 2.0 g/dish, bar 4; 4.0 g/dish, bars 1 and 5). At
48 h after transfection cells were lysed, and 10 g of the lysates was immunoblotted and revealed with anti-p63 and anti-p14ARF antibodies.
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sulted in a progressive reduction of TAp63-driven transcrip-
tion up to the background level. Similar results were obtained
when Np63 was used as transactivator (Fig. 3B). On the
other hand, when p14ARF was cotransfected with p53 by the
same experimental procedure, we did not observe reduction
but a slight increase of p53-driven transcription (Fig. 3C), in
agreement with the known function of ARF.
At first, we reasoned that a decrease in the p63 protein level
could account for the observed inhibition of p63 transcrip-
tional activity by p14ARF. On the other hand, it has been shown
that ARF is able to promote polyubiquitination and degrada-
tion of proteins such as E2F1 (6) and B23 (15). Therefore, we
decided to check whether or not p14ARF affects the level of p63
exogenous protein. To this aim, we compared levels of p63
protein with or without ARF coexpression. We transfected
into Saos-2 cells p63 alone or p63 with p14ARF and examined
the level of exogenous p63 protein by Western blotting. As
shown in Fig. 3D and E, the abundance of transfected TAp63
and Np63 proteins remained unchanged upon p14ARF over-
expression.
To validate our data, we felt it was important to show a
correlation between the decrease of p63 transactivation poten-
tial by p14ARF and modulation of endogenous target genes.
For this reason, we checked the expression of p21WAF and
MDM2 endogenous genes upon transfection of TAp63 alone
or with increasing amounts of p14ARF. For this experiment, we
used the H1299 cells. In mock-transfected cells endogenous
p21WAF protein was detectable, whereas no MDM2 was ob-
served (Fig. 4). As shown in Fig. 4, endogenous p21WAF and
MDM2 proteins were both induced by transfection of TAp63
alone (compare lanes 1 and 3); the addition of increasing
amounts of p14ARF efficiently repressed this induction in a
dose-dependent way (compare lane 3 with lanes 4 to 7). Again,
the level of TAp63 protein appeared to be unaffected by
p14ARF coexpression. These results are consistent with our
data from CAT reporter assays.
The p63 transcriptional activity in the presence of p14ARF
was also investigated in repression assays with the Hsp70 pro-
moter. The Hsp70 promoter has a high level of intrinsic activity
even without activation by heat shock and is efficiently re-
pressed by p53 (1). Saos-2 cells were cotransfected with the
Hsp70CAT construct, a fixed amount of each of the different
p63 constructs, with or without a fixed amount of p14ARF
plasmid DNA. According to a previous report (11), all p63
isoforms, with the exception of Np63, are able to transre-
press this promoter. As shown in Fig. 5, even though to a
different extent, p14ARF was able to decrease the ability of both
TA and Np63 isoforms to transrepress the Hsp70 promoter.
It is noteworthy that p14ARF alone causes a decrease of the
basal activity of the Hsp70 promoter. Taken together, these
data suggest that p14ARF is able to inhibit both activation and
repression of p53-target promoters by p63, leaving unaltered
the intracellular p63 protein level.
Physical interaction of TA and Np63 with p14ARF in mam-
malian cells. In searching for a mechanism for ARF inhibition
of p63-driven transcription, we decided to examine whether
ARF can associate with p63. Human ARF was expressed alone
or together with TA or Np63 into the ARF-null NIH 3T3
cells to perform coimmunoprecipitation assays. NIH 3T3 cells
did not have detectable p63 endogenous protein. Using anti-
human ARF polyclonal antibodies, coimmunoprecipitation of
TA and Np63 (Fig. 6A), TA and Np63 (Fig. 6B), or TA
and Np63 (Fig. 6C), occurred only when each of these
proteins was coexpressed with p14ARF; p63-p14ARF complexes
were not found when either protein alone was expressed in
cells. Similar results were obtained when the cellular lysates
were immunoprecipitated with anti-p63 antibodies (Fig. 6D
and data not shown). The interaction between p14ARF and TA
or Np63 and  isoforms was also observed in H1299 cells in
FIG. 4. Induction of endogenous MDM2 and p21WAF upon p63
transfection is counteracted by p14ARF cotransfection. Immunoblot
analysis of total protein lysates from H1299 cells cotransfected with a
fixed amount of TAp63 (0.5 g/dish, lanes 3 to 7) and increasing
amounts (0.5 g/dish, bar 4; 1 g/dish, bar 5; 2 g/dish, bar 6; 4
g/dish, bars 2 and 7) of p14ARF-expressing plasmids was performed.
An anti-actin antibody was used for normalization of cell lysate load-
ing.
FIG. 5. p14ARF counteracts p63-dependent transrepression. Saos-2
cells were cotransfected with a fixed amount of Hsp70 reporter plasmid
(0.25 g/dish), 0.1 g of the indicated p63 expression plasmids, and 0.4
g of p14ARF-expressing plasmid (open bars) or 0.4 g of pcDNA
(gray bars). The basal activity of the reporter was set to 1. The data are
presented as the fold repression relative to the sample without effector.
Each histogram bar represents the mean of three independent trans-
fection duplicates. The standard deviations are indicated.
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a similar experimental procedure (Fig. 6E and data not
shown).
Moreover, to confirm the observed interaction in a more
physiological context, we performed an immunoprecipitation
experiment into HaCaT cells, a spontaneously immortalized
keratinocyte cell line expressing detectable levels of endoge-
nous Np63. Since no endogenous p14ARF protein was re-
vealed, HaCaT cells were transiently transfected with a
p14ARF-expressing plasmid. Cellular extracts were incubated
with anti-human ARF antibodies. Immunoprecipitates were
blotted and probed with anti-p63 and anti-p14 antibodies. As
shown in Fig. 6F, Np63 was coimmunoprecipitated only
when p14ARF is expressed. This experiment confirmed that a
complex between p14ARF and p63 occurs in mammalian ker-
atinocyte cells.
To identify the region of p63 essential for the interaction
with p14ARF, three deletion mutants of p63 were constructed
starting from the TAp63 or Np63 wild-type constructs. A
schematic representation of these mutants is shown in Fig. 7A.
First, we verified by Western blotting that the mutant proteins
were correctly expressed upon transfection into NIH 3T3 cells.
As shown in Fig. 7B, with the exception of the 1-86 mutant,
which appears to be relatively less abundant, the expression
level of the tested mutants was comparable to that of wild-type
TAp63. Each mutant was assayed in NIH 3T3 cells for its
interaction with p14ARF by coimmunoprecipitation experi-
ments. Removal of the carboxy-terminal portion (297-449
mutant) encompassing the entire TID, SAM, and OD domains
of TAp63 does not impair p63-ARF interaction (Fig. 7C). On
the other hand, deletion of either amino acids from 1 to 86
(1-86 mutant), including both the TA2 and the PRD do-
mains, or the first 26 amino acids of Np63 (1-26 mutant),
encompassing only the TA2 domain, completely abolished
p63-p14ARF interaction (Fig. 7D).
FIG. 6. Coimmunoprecipitation of TA and N p63 proteins with p14ARF. NIH 3T3 cells were transfected with 1 g of expression plasmids
encoding TA or Np63 (A), TA or Np63 (B), and TA or Np63 (C and D) alone or together with 2 g of p14ARF-expressing plasmid.
Cellular extracts were immunoprecipitated with anti-ARF antibodies (A, B, and C) or with anti-p63 antibodies (D). Immunocomplexes were
analyzed with anti-p63 and anti-p14ARF antibodies. (E) H1299 cells were transfected with 1 g of expression plasmids encoding TA or Np63
alone or together with 2 g of p14ARF-expressing plasmid. Cellular extracts were immunoprecipitated with anti-ARF antibodies and analyzed with
anti-p63 and anti-p14ARF antibodies. (F) HaCaT cells were transfected with 2 g of p14ARF-expressing plasmid. Cellular extracts were incubated
with anti-ARF antibodies or, as control, with an unrelated antibody. Immunocomplexes were analyzed with anti-p63 and anti-p14ARF antibodies.
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To define which parts of the ARF protein are required for
the physical interaction with p63, we performed coimmuno-
precipitation of in vitro-cotranslated proteins. We assayed two
deletion mutants: the first lacking amino acids from 66 to132
(p14ARF66-132) and the second lacking the N-terminal 1 to
38 amino acids (p14ARF1-38) (Fig. 8A). We were able to
show that deletion of amino acids 1 to 38 (Fig. 8B, compare
lanes 2 and 3) impairs the interaction with p63, whereas the
C-terminal portion of the protein appears to be dispensable for
the interaction (Fig. 8B, lane 4).
ARF decreases the binding of p63 to a p53 DNA-binding site
in the p21WAF promoter. Since we have found that ARF binds
to p63 and inhibits p63-driven transcription, we decided to
examine whether p14ARF impairs the binding of p63 to a ca-
nonical p53 consensus sequence. We thus compared the bind-
ing of p63 in presence or absence of ARF. We performed an in
vitro DNA-binding assay using, as a target DNA, a radiola-
beled duplex oligonucleotide representing a p53-binding site
previously identified in the p21WAF promoter (44). Incubation
of the radiolabeled oligonucleotide with in vitro-translated
TAp63 led to the formation of a specific protein-DNA com-
plex (Fig. 9A, lane 1). The specificity of the TAp63-DNA
complex was tested by a competition experiment: a 100 cold
molar excess of the same oligonucleotide used as a probe
completely abolished the binding, whereas a nonrelevant con-
trol oligonucleotide had no effect (Fig. 9A, lanes 1, 2, and 3).
The identity of the TAp63-DNA complex was confirmed by a
supershift experiment (Fig. 9A, lanes 4, 5, 6, and 7) in which
the in vitro-translated TAp63 protein was incubated prior to
the binding reaction with an antibody recognizing the poly-His
tag fused upstream of the coding region of TAp63, with a
nonrelevant anti-p21 antibody as a control and with an anti-
body recognizing the p63 DNA-binding domain. Interestingly,
when TAp63 was cotranslated with p14ARF, the binding was
significantly reduced (Fig. 9A, lanes 11 and 12). A Western
blot analysis of the in vitro-translated proteins showed no sig-
nificant differences in the relative abundance of the TAp63
protein translated alone or in presence of p14ARF (Fig. 9B).
These observations indicate that TAp63 specifically binds to a
p53 consensus in the p21WAF promoter and that p14ARF im-
pairs this binding.
p63 relocalizes ARF in the nucleoplasm. The p14ARF pro-
tein is mainly located into nucleoli. The nucleolar localization
of ARF is even more predominant when it is transiently over-
FIG. 7. Identification of p63 domains involved in p14ARF interaction. (A) Schematic representation of the p63 deletion constructs used in this
experiment. (B and C) NIH 3T3 cells were transfected with 1 g of expression plasmids encoding wild-type TAp63 or the indicated p63 deleted
constructs alone or together with 2 g of p14ARF-expressing plasmid. Cellular extracts were immunoprecipitated with anti-ARF antibodies.
(D) Equal amounts of total protein extracts from cells transfected with the indicated plasmids were immunoblotted with anti-p63 antibodies.
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expressed or expressed in a subset of p53-deficient tumor cell
lines (21). Moreover, ARF is able to sequester its binding
partners, in particular MDM2 and E2F1, to this location (6,
42). We reasoned that a possible mechanism through which the
p14ARF protein could inhibit the transcriptional activity of p63
is by sequestering it into the nucleolus where it cannot perform
its transcriptional functions. To investigate this hypothesis, we
first monitored the subcellular localization of ectopically trans-
fected p63 isoforms.
Therefore, TA and Np63 isoforms were produced as green
fluorescent protein (GFP) fusion proteins and expressed in
H1299, COS-7, Saos-2, and NIH 3T3 cell lines. The  and 
isoforms of both TA and Np63 exhibited a very similar local-
ization pattern in the various cell lines, i.e., they were uni-
formly distributed in the nucleus with nucleolar sparing. A
different pattern was observed for the TAp63 and Np63
proteins that appeared to be distributed both in the nucleus
and cytoplasm. Again, we did not observe TAp63 or Np63
proteins in the nucleoli. Moreover, most TAp63 and Np63
expressing cells showed nuclear and cytoplasmic dots that were
often located on the surface of the nuclear membrane (data
not shown). Similar results were obtained when cells express-
ing TA and Np63 isoforms lacking the GFP domain were
revealed with anti-p63 antibodies (data not shown).
In agreement with previous observations, we found that
transfected p14ARF accumulates predominantly into the nucle-
oli of NIH 3T3, COS-7, Saos-2, and H1299 (39, 42). In the
remaining cells it shows a diffuse nuclear distribution or a
nuclear distribution with nucleolar sparing (Fig. 10A and Table
1). B23 anti-nucleolin antibody was used in these experiments
as a control for nucleolar localization (data not shown). When
p63 and ARF were cotransfected in a 1-to-1 ratio, the above-
described subcellular distribution of p63 proteins remained
unaltered (data not shown). Unexpectedly, a large percentage
of cells expressing both TAp63 isoforms and ARF proteins
exhibited a complete exclusion of p14ARF from nucleoli. The
results obtained with TAp63 are shown as a representative
example (Fig. 10B). Conversely, no significant change of the
typical subcellular distribution of p14ARF was seen when
p14ARF was cotransfected either with Np63 isoforms (see
Table 1) or p53 (data not shown). According to the above
results, the C-terminal deleted (297-449) TAp63 protein ef-
ficiently induced p14ARF nucleolar exclusion, whereas the
1-26 and the 1-86 proteins were ineffective, underlining the
importance of the p63 amino-terminal region in this phenom-
enon (Table 1).
Remarkably, the TAp63 isoform appears to be significantly
less efficient than the other TA isoforms in mediating the
exclusion of ARF from the nucleolus. However, when increas-
ing amounts of TAp63 plasmid were cotransfected in COS-7
cells, with a fixed amount of ARF-expressing plasmid, the
proportion of cells showing ARF nucleolar localization de-
creased in a dose-dependent manner up to 40% (Fig. 11).
DISCUSSION
We present here evidence indicating a physical and func-
tional relationship between p63 and p14ARF. To our knowl-
edge, this is the first report that supports an intimate associa-
tion between p14ARF and a member of the p53 family. Our
data indicate that p63 is able to associate with p14ARF, both in
the TA and N versions, in different mammalian cell lines.
Coimmunoprecipitation experiments of in vitro-translated pro-
teins support the conclusion that a direct physical association
between p14ARF and p63 occurs. By deletion analysis, we have
shown that this interaction is mediated by the N-terminal re-
gion from amino acids 1 to 26 of Np63. Remarkably, only 12
amino acids of this region (encompassing amino acids 15 to 26
of Np63 and amino acids 109 to 120 of TAp63) are in com-
mon between TA and N isoforms. Since interaction between
FIG. 8. Immunoprecipitations of in vitro-translated proteins and mapping of the p14ARF domain involved in p63 interaction. (A) Schematic
representation of the p14ARF deletion constructs used in this experiment. (B) A total of 40 l of in vitro-translated 35S-labeled TAp63 alone (lane
1) or cotranslated with either p14ARF (lane 2), p14ARF(1-38) (lane 3), or p14ARF(66-132) (lane 4) was immunoprecipitated with anti-His
antibodies (recognizing the poly-His tag fused to the 5	 of the coding region of wild-type and mutant p14ARF). The immunocomplexes were
analyzed on an SDS–15% polyacrylamide gel and detected by autoradiography. (C) A total of 5 l of in vitro-translated proteins used in the
above-described immunoprecipitations was analyzed on an SDS–15% polyacrylamide gel and then detected by autoradiography.
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p63 and p14ARF occurs with both TA and N isoforms, we
infer that this stretch of 12 amino acids contains residues that
might be crucial for p63-p14ARF association. On the other
hand, the p63 C-terminal region seems to be dispensable for
p14ARF-p63 binding. Two distinct observations support this
hypothesis; first, p63 proteins with either the , , or  alter-
native type of carboxy-terminal equally associate with p14ARF
and, second, the (297-449)TAp63 mutant, in which the entire
TID, SAM and OD domains were removed, is still able to
interact with p14ARF.
Our results suggest that the ARF carboxy-terminal portion is
dispensable for the ARF-p63 interaction, whereas the N-ter-
minal region seems to be involved. It has been reported (22)
that the first N-terminal 22 amino acids of p14ARF retain the
ability to bind MDM2, but a second, less-efficient, MDM2-
binding site is present in the ARF carboxy-terminal region.
However, a more accurate definition of the region of ARF
interacting with p63 is necessary to verify whether the MDM2-
ARF binding overlaps with the p63-ARF binding.
Normally, the ARF protein localizes in the nucleolus. How-
ever, we found that p63 proteins are all prevalently localized in
the nucleoplasm and excluded from nucleolus. Interestingly,
we have noticed a remarkable decrease of the nucleolar frac-
tion and a corresponding increase in the nucleoplasmic frac-
tion of p14ARF upon TAp63 overexpression, findings that sup-
port a physical association between the two proteins. The
importance of the amino-terminal TA domain in promoting
p14ARF nucleolar exclusion is emphasized by the observation
that N isoforms leave unaltered ARF nucleolar localization,
whereas the TAp63(297-449) mutant shows the same be-
havior of the  and  TAp63. The question remaining is why
TAp63 appears to be less efficient than the other TAp63
isoforms in promoting ARF nucleolar exclusion. Concerning
this point we recall that the extreme C-terminal domain (TID),
unique to the  isoforms, binds to the N-terminal TA domain
through an intramolecular interaction. This binding is both
necessary and sufficient for protein stabilization and transcrip-
tional inhibition of TAp63 (32). Thus, we suggest that such
intramolecular association could, in a similar way, mask se-
quences located in the TA domain that are responsible for
p14ARF nucleolar exclusion. The mechanism by which coex-
pression of TAp63 isoforms and p14ARF alters the subcellular
localization of p14ARF is under investigation; however, we
think that residues located in the TA domain of p63 might
increase the binding affinity between p63 and p14ARF so that,
once established, the complex keeps p14ARF in the nucleoplas-
mic compartment. However, we cannot exclude that interac-
tion of p14ARF with the TA domain of p63 might hamper
association with additional molecular partners that regulate
p14ARF nucleolar import.
The ARF tumor suppressor acts as a sensor of hyperprolif-
FIG. 9. Protein DNA-binding assay. (A) A 40-bp radiolabeled oligonucleotide containing a p53-binding site was incubated with in vitro-
translated TAp63. The specificity of the binding was assessed by competition with either a 100 cold molar excess of the same oligonucleotide
used as a probe or of an unrelated oligonucleotide (compare lane 1 to lanes 2 and 3). Supershift (lanes 4 to 7) was carried out with anti-His
antibodies (recognizing the poly-His tag fused to the 5	 of the coding region of TAp63) (lane 5), anti-p63 antibody (recognizing the DNA-binding
domain of p63) (lane 7) or, as a control, anti-p21 antibody (lane 6). The binding reaction was also carried out, as a control, with the rabbit
reticulocytes (lane 9) and with in vitro-translated p14ARF (lane 8). Binding reactions with TAp63 translated alone (lane 11) or cotranslated with
p14ARF (lane 12) are shown. (B) The same aliquots of in vitro-translated TAp63 or TAp63/ARF used in the above-described binding reactions
were analyzed by Western blotting with anti-His and anti-ARF antibodies.
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erative signals emanating from oncoproteins and inducers of
S-phase entry, such as Myc, E1A, Ras, and E2F-1 (reviewed in
reference 33). ARF, in turn, triggers p53-dependent growth
arrest in the G1 and G2 phases of the cell cycle or, in the
presence of appropriate collateral signals, sensitizes cells to
apoptosis. ARF binds directly to MDM2, enabling transcrip-
tionally active p53 to accumulate in the nucleoplasm (43); (42).
Emerging evidence suggests that ARF can, though less effi-
ciently, suppress the proliferation of cells that express mutant
p53 or lack both MDM2 and p53, implying the existence of
p53/MDM2-independent functions of ARF working through
interactions with other regulators (41).
Very recently, it has been reported that ARF may function
in coordinating cell growth with proliferation through its in-
teraction with B23, a nucleolar protein involved in ribosome
biogenesis. Inducing B23 degradation, p14ARF inhibits rRNA
processing (15, 35). Thus, it is possible that the phenomenon of
ARF nucleolar exclusion may interfere with the specific role of
ARF in controlling ribosome biogenesis. Further investiga-
tions are necessary to clarify this point.
Other p53-independent functions of ARF include repression
of E2F (9) and NF-B (31) activity. Various proteins that
associate with ARF have been identified, including Spinophilin
(39), MdmX, Pex19, CARF, a novel serine-rich protein (30),
and Tat binding protein 1 (27). However, the extent to which
these ARF complexes modulate the cell cycle inhibitory action
of ARF is not well established.
Interestingly, our data show that p14ARF inhibits the ability
of p63 to enhance the expression of various endogenous genes.
Moreover, since we have shown the inhibitory function of ARF
on both p63 transactivation and transrepression assays, it ap-
pears that p14ARF antagonizes p63 whatever is the activity of
p63 on that particular promoter. Actually, we could test this
phenomenon only on p53 target promoters such as p21WAF,
Apaf1, and Hsp70 because no specific p63 targets have been
identified thus far. If this phenomenon is also observed on
FIG. 10. TAp63 impairs p14ARF nucleolar localization. COS-7 cells were seeded on glass coverslips and transfected with 0.5 g of expression
vector encoding p14ARF (A) or cotransfected with 0.5 g of p14ARF and 0.5 g of GFP::TAp63 fusion protein (B). The cells were examined under
a fluorescence microscope (Nikon). All images were digitally processed by using Adobe Photoshop. The subcellular localization of GFP::TAp63
and p14ARF are shown. Numerical data indicate the percentage of cells showing different ARF localizations.
TABLE 1. Percentage of cells showing nucleolar localization of p14ARF upon cotransfection of p14ARF (0.5 g) with the indicated p63
isoforms (0.5 g) in Saos-2, H1299, and NIH 3T3 cells and the percentage of cells showing nucleolar localization of p14ARF upon
cotransfection of p14ARF (0.5 g) with the indicated wild-type or mutant p63 isoforms (0.5 g) in COS-7 cellsa
Cell line
% of cells (mean  SD) showing localization of p14ARF upon cotransfection with:
pcDNA TA TA TA N N N TA(297–449) N(1–26) N(1–86)
Saos-2 90  3 39  5 ND 26  2 85  2 ND 90  5
H1299 93  3 40  7 ND 10  5 86  4 ND 88  3
NIH
3T3
90  5 40  5 10  5 10  3 97  2 90  5 95  3
COS-7 95  2 85  5 30  3 35  5 96  3 94  5 95  3 27  3 96  2 95  3
a Numerical data represent the means of three independent experiments. ND, not determined.
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p63-specific target promoters, it would indicate a more general
role, one not necessarily involving p53.
We have previously reported that overexpression of MDM2
induces TAp63 protein stabilization and transcriptional activa-
tion and that both effects are counteracted by ARF coexpres-
sion (3). In principle, one could reasonably suggest that the
observed inhibitory effect of p14ARF on p63-dependent tran-
scription might be due, at least in MDM2-expressing cells, to
the well-described antagonistic effect that p14ARF exerts on
MDM2. Actually, two different considerations argue against
this hypothesis. First, we observed that p14ARF inhibition of
p63-dependent transcription does not correlate with any de-
crease in p63 protein intracellular levels. Second, our data
demonstrate a direct interaction between p14ARF and p63,
whereas the relationship between ARF and p53 is mediated by
MDM2.
The discovery of the p53 homologs has sparked speculation
on how surveillance of cellular integrity might be achieved
through the network of p53-like proteins characterized by sim-
ilar structural and biochemical properties. Actually, both p63
and p73 share several p53 transcriptional gene targets and can
induce apoptosis and cell growth arrest. Increasing evidence
points to highly tissue specific mechanisms and differential
regulation as the principal factors accounting for the majority
of the differences in biological function (3, 40).
Recent studies demonstrated that among the p63 proteins
TAp63 isoforms are the first to be expressed during embryo-
genesis and are required for commitment to an epithelial strat-
ification program. Np63 is the predominant isoform ex-
pressed in mature epidermis (20). Since TAp63 isoforms seem
to inhibit terminal differentiation, they must be counterbal-
anced by Np63 to allow cells to respond to signals required
for the maturation of embryonic epidermis (18). On the other
hand, UVB-induced DNA damage decreases levels of
Np63, whereas the levels of the TAp63 isoforms increase.
This mechanism is a prerequisite for UV-induced apoptosis in
the skin (20, 45).
Interestingly, it has been shown that, in epidermis, p53 is
expressed in the basal layer, where it plays a surveillance role
in progenitor and/or stem cell renewal (24). The p53 protein
acts not only to keep stem cells quiescent but also to ensure the
correct control of cell cycle and cell division as keratinocytes
proliferate. In fact, p53-deficient epidermal keratinocytes dif-
ferentiate normally, but they are affected in their growth con-
trol and underwent malignant transformation (7). On the other
hand, it is still unclear whether ARF is regulated under phys-
iological conditions, and little is understood concering its role
in adult tissue homeostasis. Our observation that p14ARF as-
sociates with p63-inhibiting p63 transcriptional activity sug-
gests, that under p14ARF overexpression, the pool of p63 pro-
teins might be kept inactive in a p63-p14ARF complex.
Hence, we speculate that under mitogenic stimuli, p14ARF
physically associate with TA and perhaps dominant-negative
p63 isoforms, removing them from p53/p63-responsive pro-
moters. This process might turn on p53 transcriptional func-
tions, activating the p53-dependent checkpoint control. Actu-
ally, our EMSA experiments show that p14ARF is able to affect
the binding of TAp63 to a canonical p53 consensus sequence,
lending support to this hypothesis. More specific experimental
in vivo approaches, such as chromium immunoprecipitation
assays, will elucidate the real contribution of ARF in the reg-
ulation of transcription of p53 target genes in their natural
setting, given the important role of chromatin structure in the
regulation of gene expression. Studies to address this question
are under way.
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